April 25th 2024
In a retrospective study, the machine learning tool was able to screen for potential risks of cardiovascular disease nearly 60 days before the patient's medical record showed any signs of a related condition or before they were officially diagnosed or treated for it.
Therapeutics Issue of Evidence-Based Diabetes Management Takes on Cost, Coverage, and Combinations
September 27th 2016Whether it’s the high cost of insulin or the question of when to start combination therapy, the new issue of Evidence-Based Diabetes Management, a publication of The American Journal of Managed Care, covers up-to-the-minute topics in this special issue on therapeutics. Editor-in-chief Robert A. Gabbay, MD, PhD, FACP, leads off this issue featuring voices of providers, pharmaceutical leaders, payers, and patients.
Read More
Minorities, Southerners in Medicare Less Likely to Take High Blood Pressure Medication
September 14th 2016The authors said this is the first study to examine antihypertension nonadherence down to the county level. Recommendations include greater use of combination therapy to reduce pill counts for patients with multiple chronic conditions, and synchronizing pharmacy visits to avoid multiple trips.
Read More
The Financial Impact of Team-Based Care on Primary Care
Although team-based care improved cardiovascular disease risk factors, it had a negative financial impact on a primary care practice.
Read More
Impact of a Physician-Led Point of Care Medication Delivery System on Medication Adherence
A point of care medication delivery system improves medication adherence to cardiovascular medications without increasing costs.
Read More
Diabetes Raises Fatal Heart Attack Risk by 50%
June 23rd 2016The study comes as regulators put increased emphasis on long-term cardiovascular outcomes trials to ensure safety of diabetes and obesity therapies. The American Journal of Managed Care recently convened an expert panel on the topic.
Read More
Value of Improved Lipid Control in Patients at High Risk for Adverse Cardiac Events
Reducing lipid levels in high-risk patients can significantly reduce disease burden and, depending on final negotiated prices, PCSK9 inhibitors can make an economic contribution to this goal.
Read More